证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-060 青岛蔚蓝生物股份有限公司 关于提前归还部分募集资金的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2023 年 1 月 17 日召开 第四届董事会第二十次会议和第四届监事会第十九次会议，审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用不超过人民币 10,000 万元的闲置募集资金暂时补充流动资金，仅限于与公司主营业务相关的 生产经营使用，使用期限自公司第四届董事会第二十次会议审议通过之日起不超 过 12 个月，到期后将及时、足额将该部分资金归还至募集资金专户。具体内容 详见公司于 2023 年 1 月 18 日在《中国证券报》《上海证券报》《证券时报》《证 券日报》和上海证券交易所网站（www.sse.com.cn）披露的《关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2023-005）。 青岛蔚蓝生物股份有限公司董事会 公司已于 2023 年 4 月 13 日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately CNY 543.94 million, a 2.13% increase compared to CNY 532.60 million in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was approximately CNY 31.47 million, representing a decrease of 15.87% from CNY 37.41 million in the previous year[17]. - The net cash flow from operating activities increased by 30.78% to approximately CNY 20.61 million, compared to CNY 15.76 million in the same period last year[17]. - The total assets of the company at the end of the reporting period were approximately CNY 2.80 billion, an increase of 8.49% from CNY 2.58 billion at the end of the previous year[17]. - The company's basic earnings per share for the first half of 2023 were CNY 0.12, down 20.00% from CNY 0.15 in the same period last year[18]. - The company reported a decrease of 28.65% in net profit after deducting non-recurring gains and losses, amounting to approximately CNY 17.27 million compared to CNY 24.21 million in the previous year[17]. - The weighted average return on net assets for the first half of 2023 was 1.91%, a decrease of 0.42 percentage points from 2.33% in the same period last year[18]. - The total comprehensive income for the period was CNY 37,117,751.72, down 13.5% from CNY 42,729,752.86 in the previous year[121]. - The company reported a net profit of CNY 44,467,557.49 for the first half of 2023, down from CNY 52,653,015.82 in the same period of 2022[120]. Research and Development - The company invested CNY 51.42 million in R&D during the first half of 2023, accounting for 9.45% of its revenue, indicating a strong commitment to innovation[40]. - The company has developed 35 proprietary probiotic strains aimed at various health benefits, with 62 invention patents and 17 utility model patents applied for, showcasing its robust R&D capabilities[38]. - The company has established a microbial strain bank capable of housing 100,000 strains, enhancing its research and development in microbial resources[35]. - The company has established 8 technology centers and 2 laboratories, employing 277 dedicated R&D personnel to drive sustainable development through technology[26]. - The company’s research and development framework includes eight technology centers and two laboratories, facilitating comprehensive innovation efforts[40]. - The company is focused on expanding its market presence in the animal health and nutrition sectors, leveraging its expertise in enzyme and microecological product development[25]. Product Offerings and Market Strategy - The company is engaged in the research, production, and sales of enzyme preparations, microbial preparations, and animal health products, focusing on providing core technology support for biological manufacturing[22]. - The company produces and sells enzyme preparations, including feed enzymes, industrial enzymes, food enzymes, and biocatalysts, targeting various industries such as animal feed, textiles, and food production[23]. - The company offers animal health products, including vaccines and veterinary medicines, aimed at preventing diseases and improving survival rates in livestock[25]. - The company aims to provide clean and energy-saving technologies for traditional industries and green solutions for food safety, serving multiple sectors including agriculture, food, and health[22]. - The company is collaborating with ADM to establish new food probiotic production capacity, capitalizing on the growing probiotic market in China[51]. - The company has expanded its product offerings to aquaculture, plants, nutrition, and health sectors, with some products exported to Europe and Asia[42]. Environmental and Sustainability Initiatives - The company emphasizes the development of sustainable agricultural solutions through its plant microecological preparations, which reduce the need for chemical fertilizers and pesticides[25]. - The company’s enzyme technology promotes energy savings and reduces carbon emissions in various industries, including animal feed and textiles[79]. - The company’s micro-ecological products effectively reduce nitrogen, phosphorus, and sulfur emissions from livestock waste, contributing to environmental protection[80]. - The company’s initiatives in waste treatment enhance the efficiency of waste fermentation and promote resource utilization[81]. - The company has complied with national environmental regulations and maintained a strong commitment to environmental protection throughout its operations[78]. - The company implemented carbon reduction measures, achieving a reduction of 1,071,600 tons of CO2 equivalent emissions[82]. Financial Position and Assets - The company's total assets as of June 30, 2023, were CNY 2,554,138,220.21, an increase of 7.46% from CNY 2,376,502,301.20 at the end of 2022[119]. - The company's total liabilities rose to CNY 1,051,750,786.83 from CNY 844,934,231.18, marking an increase of around 24.5%[116]. - The total equity of the company as of June 30, 2023, was CNY 1,746,034,729.28, slightly up from CNY 1,733,913,405.80, indicating a marginal increase of approximately 0.7%[116]. - The company's total current assets reached CNY 1,100,929,315.12, up from CNY 969,399,325.09, indicating an increase of about 13.5%[115]. - The company's total equity attributable to shareholders was CNY 1,216,735,408.15, a decrease of 2.09% from CNY 1,242,976,443.98 at the end of 2022[119]. Market Trends and Competition - The enzyme and micro-ecological preparation industry is in a growth phase, benefiting from increasing national emphasis on safety and environmental protection, with a broad market outlook[28]. - The demand for enzyme preparations is expected to grow due to rising environmental standards and the need for effective waste management solutions[29]. - The animal health industry is undergoing consolidation due to overcapacity and product homogenization, favoring companies with technological and brand advantages[32]. - The increasing consumer awareness of food safety is driving the demand for enzyme and micro-ecological preparations to reduce antibiotic reliance[30]. - The company faces market competition risks in the enzyme preparation and animal health industries, which could lead to performance declines if not addressed[68]. Corporate Governance and Compliance - The company has maintained a strong commitment to corporate governance and compliance, ensuring transparency in all operations[94]. - There were no significant legal disputes or regulatory issues reported during the period[94]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[73]. - The company has undergone changes in its board of directors, with new appointments including Chen Gang as chairman[73]. Future Outlook and Guidance - The company provided guidance for the next quarter, expecting revenue to be between 1.6 billion and 1.8 billion, indicating a potential growth of 7% to 20%[89]. - The company plans to focus on market expansion and new product development in the upcoming quarters[121]. - New product launches are expected to contribute an additional 300 million RMB in revenue by the end of the year[92]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the tech sector[92].

青岛蔚蓝生物股份有限公司 证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-056 关于公司第五届监事会第二次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届监事会第二次会议 于 2023 年 8 月 24 日在公司会议室以通讯和现场表决的方式召开，会议通知已于 2023 年 8 月 14 日以邮件形式发出。本次会议应出席监事 3 人，实际出席 3 人。 会议由公司监事会主席原妤女士主持。会议召集召开程序及审议事项符合《中华 人民共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成 的决议合法有效。 青岛蔚蓝生物股份有限公司监事会 2023 年 8 月 25 日 具体内容详见公司在上海证券交易所网站(www.sse.com.cn)披露的《青岛蔚 蓝生物股份有限公司 2023 年半年度报告》及《青岛蔚蓝生物股份有限公司 2023 年半年度报告摘要》。 表决结果：3 票赞成，0 票反对，0 票弃权。 2、审议通过《 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-059 青岛蔚蓝生物股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2023 年 8 月 22 日(星期二)至 8 月 28 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 vland@vlandgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 青岛蔚蓝生物股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度的经营成果、财务状况，公司计划于 2023 年 8 月 29 日上午 09:00-10:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 ...

二、报告期经销商变动情况 | 地区 | | 2023 年第二季度 | | | | --- | --- | --- | --- | --- | | | 期初 增加 | | 减少 | 期末 | | 东北 | 41 | 26 | 18 | 49 | | 华北 | 110 | 43 | 56 | 97 | | 华东 | 456 | 130 | 241 | 345 | | 华南 | 61 | 13 | 24 | 50 | | 华中 | 87 | 27 | 38 | 76 | | 西北 | 18 | 7 | 11 | 14 | | 西南 | 48 | 7 | 26 | 29 | | 总计 | 821 | 253 | 414 | 660 | 三、报告期内无其他对公司生产经营具有重大影响的事项。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-058 青岛蔚蓝生物股份有限公司 2023 年度第二季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）根据上海证券交易所《 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-055 表决结果：5 票赞成，0 票反对，0 票弃权。 2、审议通过《关于<公司 2023 年半年度募集资金存放与实际使用情况的专 项报告>的议案》 具体内容详见公司在上海证券交易所网站(www.sse.com.cn)披露的《青岛蔚 蓝生物股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告》 （公告编号：2023-057）。 青岛蔚蓝生物股份有限公司 关于公司第五届董事会第三次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届董事会第三次会议 于 2023 年 8 月 24 日在公司会议室以通讯和现场表决的方式召开，会议通知已于 2023 年 8 月 14 日以邮件形式发出。本次会议应出席董事 5 人，实际出席 5 人。 会议由公司董事长陈刚先生主持。会议召集召开程序及审议事项符合《中华人民 共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成的 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-057 青岛蔚蓝生物股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》及相关格式指引的规定，青岛蔚蓝生物股份有限公 司（以下简称"公司"）现将 2023 年半年度募集资金存放与实际使用情况专项说 明如下： 一、募集资金基本情况 （一）首次公开发行募集资金 1、实际募集资金金额及资金到账时间 经中国证券监督管理委员会证监许可[2018]1961 号文核准，公司向社会公 众公开发行人民币普通股(A 股)股票 3,866.70 万股，发行价为每股人民币 10.19 元，共计募集资金 394,016,730.00 元，扣除各项发行费用后，实际募集资金净 额为人民币 347,440,291.00 元。上述募集资金已于 2019 年 1 月 9 日到位，已经 瑞华会计师事务所（特殊普通合伙）验证，并由其出具《验资 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-054 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易概述 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2023 年 7 月 20 日召开 了第五届董事会第二次会议，以"5 票赞成、0 票反对、0 票弃权"的表决结果 审议通过了《关于收购青岛润博特生物科技有限公司 51%股权的议案》，同意公 司以自有资金 9,180 万元收购秦伟、秦启龙、张小东、陈强、青岛聚润管理咨询 合伙企业（有限合伙）和青岛格润普管理咨询合伙企业（有限合伙）合计持有的 青岛润博特生物科技有限公司（以下简称"润博特"）51%的股权。具体内容详见 公司于 2023 年 7 月 21 日在上海证券交易所网站（www.sse.com.cn）披露的《青 岛蔚蓝生物股份有限公司关于收购青岛润博特生物科技有限公司 51%股权的公 告》（公告编号：2023-051）。 二、本次交易进展情况 公司于 2023 年 8 月 16 日收到润博特的通知，润博特已办理完成本次收购相 关的工商变更手续，并 ...

Financial Performance - In 2022, the company's operating revenue was CNY 1,163,162,781.39, representing a 1.07% increase compared to CNY 1,150,823,565.24 in 2021[24]. - The net profit attributable to shareholders of the listed company decreased by 47.32% to CNY 69,842,007.67 from CNY 132,573,196.74 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 39,713,591.08, down 57.86% from CNY 94,250,882.18 in 2021[24]. - The net cash flow from operating activities increased by 6.47% to CNY 95,306,379.54 compared to CNY 89,513,699.66 in 2021[24]. - The total assets of the company at the end of 2022 were CNY 2,578,847,636.98, a 16.07% increase from CNY 2,221,761,016.76 in 2021[24]. - The net assets attributable to shareholders of the listed company increased by 2.50% to CNY 1,644,694,382.39 from CNY 1,604,515,615.36 in the previous year[24]. - Basic earnings per share decreased by 48.15% to CNY 0.28 from CNY 0.54 in 2021[25]. - The diluted earnings per share also fell by 50.00% to CNY 0.27 compared to CNY 0.54 in the previous year[25]. - The weighted average return on net assets decreased by 5.12 percentage points to 4.30% from 9.42% in 2021[25]. - Operating costs rose to CNY 660,311,201.51, reflecting a 6.76% increase year-over-year[68]. - The overall gross margin for the company was 43.21%, which decreased by 2.61% compared to the previous year[100]. Research and Development - The company invested RMB 102.40 million in R&D, accounting for 8.80% of its operating revenue, which is relatively high in the industry[31]. - The company’s R&D expenses were CNY 102,396,593.49, a 1.45% increase from the previous year[68]. - The company has established a Nutrition and Health Technology Center, developing 16 proprietary probiotic strains and filing 57 invention patents related to probiotics[50]. - The company added 51 domestic authorized invention patents and 1 U.S. patent in 2022, bringing the total to 335 domestic authorized invention patents, 8 U.S. patents, and 2 European patents by the end of the reporting period[60]. - The company has established a national engineering technology research center for animal health products, enhancing its R&D capabilities[66]. - The company has a stable team of 278 R&D personnel, which increased by 5.3% year-on-year, including 29 PhDs and various recognized talents[64]. - The company has established multiple new technology platforms for vaccine development, including cell suspension culture and bacterial fermentation technology[101]. - The company is in the laboratory research phase for several vaccine development projects, indicating ongoing innovation efforts[114]. Market Expansion and Strategic Initiatives - The company is expanding its production capacity with the launch of the animal health industry park and the completion of the plant-based micro-ecological preparation project[32]. - A joint venture with ADM has been established to produce and sell probiotic products, targeting the global market[36]. - The company is positioned to capitalize on the growing market for functional probiotics, which are increasingly recognized for their health benefits[43]. - The company is actively addressing the challenges in the animal health industry, which faces issues such as overcapacity and product homogenization, through strategic mergers and acquisitions[45]. - The company is expanding its market presence in various sectors, including industrial, food, energy, and biocatalysis, while breaking international monopolies in some areas[61]. - The company is focusing on expanding its market presence in the enzyme and probiotic sectors, which are currently dominated by foreign brands, indicating significant potential for domestic growth[131]. - The company plans to enhance its market presence through strategic partnerships and potential acquisitions in the veterinary pharmaceutical sector[95]. Environmental and Sustainability Efforts - The company aims to achieve energy savings and emissions reductions of 30%-50% compared to traditional petrochemical routes, with future potential reaching 50%-70%[199]. - The company has invested approximately 4.37 million yuan in environmental protection during the reporting period[191]. - The enzyme products sold by the company reduced carbon dioxide emissions by approximately 2,089,405 tons in 2022[196]. - The company's phytase products reduced the use of dicalcium phosphate by approximately 67,140 tons, leading to a reduction of 107,400 tons of phosphorus emissions[192]. - The company has a commitment to sustainable practices, including the use of clean energy and new technologies to improve production efficiency and quality[196]. - The company adheres to environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[191]. Governance and Management - The company maintains strict independence from its controlling shareholder, ensuring a robust governance structure and compliance with legal regulations[151]. - The total pre-tax remuneration for the board members amounted to 384.26 million CNY for the reporting period[156]. - The company has a strong leadership team with extensive experience in the agricultural and biotechnology sectors, as evidenced by the backgrounds of its board members[159]. - The company is committed to transparency and governance, as indicated by the detailed reporting of board member remuneration and shareholding changes[156]. - The company has established specialized committees under the board, including the Audit Committee and the Compensation and Assessment Committee[167]. - The company has implemented a risk prevention-oriented management approach to enhance the effectiveness of internal control systems and improve operational efficiency[188]. Product Development and Innovation - The company is focusing on the development of new vaccines for respiratory diseases in poultry, including a new live vaccine for Newcastle disease and infectious bronchitis[97]. - The company has developed a series of functional microbial agents for animal microecology, focusing on improving feed efficiency and providing solutions for green farming[49]. - The company has achieved breakthroughs in core technologies, including protein engineering and fermentation processes, positioning itself with a high level of R&D capability in the enzyme preparation industry[46]. - The company is actively involved in environmental microbiology technology, which is gaining traction due to its low energy consumption and effectiveness in pollution control[134]. - The company is developing functional feed enzymes to reduce costs in the livestock industry, including mycotoxin-degrading enzymes and new glucose oxidases[139]. Financial Management and Profit Distribution - The company plans to distribute cash dividends of 1.60 yuan per 10 shares, totaling approximately 40.33 million yuan (including tax) based on the total share capital of 252,084,840 shares[179]. - The company maintains a profit distribution policy that prioritizes cash dividends, aiming for at least 15% of the distributable profit to be allocated as cash dividends annually[175]. - The total cash dividend amount (including tax) is CNY 25,262,166.60, which represents 36.17% of the net profit attributable to ordinary shareholders in the consolidated financial statements[182]. - The company has not proposed a cash profit distribution plan despite having a positive profit available for distribution to shareholders[181].

Financial Performance - The company's operating revenue for Q1 2023 was ¥232,557,094.68, representing a decrease of 9.14% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥10,562,755.37, down 41.59% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,780,045.44, a decline of 60.66% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.04, reflecting a decrease of 42.86% year-on-year[5] - Total operating revenue for Q1 2023 was ¥232,557,094.68, a decrease of 9.1% compared to ¥255,961,097.43 in Q1 2022[15] - Net profit for Q1 2023 was ¥12,552,054.99, a decline of 36.8% from ¥19,848,538.25 in Q1 2022[16] - Total comprehensive income for Q1 2023 was CNY 12,479,517.70, a decrease of 36.9% from CNY 19,790,305.06 in Q1 2022[17] - Basic and diluted earnings per share for Q1 2023 were CNY 0.04, down from CNY 0.07 in Q1 2022[17] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥2,629,967,029.91, an increase of 1.98% from the end of the previous year[6] - The company's total assets increased to ¥2,629,967,029.91 in Q1 2023, up from ¥2,578,847,636.98 in Q1 2022, reflecting a growth of 2.0%[13] - Total liabilities rose to ¥884,744,898.05 in Q1 2023, compared to ¥844,934,231.18 in Q1 2022, marking an increase of 4.7%[12] - The equity attributable to shareholders at the end of Q1 2023 was ¥1,660,757,522.07, up 0.98% from the end of the previous year[6] - The total equity attributable to shareholders increased to ¥1,660,757,522.07 in Q1 2023, compared to ¥1,644,694,382.39 in Q1 2022[13] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥13,421,624.00, not applicable for year-on-year comparison[5] - Net cash flow from operating activities was CNY 13,421,624.00, compared to a negative cash flow of CNY -11,679,628.80 in the same period last year[18] - Net cash flow from investing activities was CNY -107,823,654.78, an improvement from CNY -194,348,403.12 in Q1 2022[19] - Cash inflow from financing activities was CNY 98,389,603.20, an increase from CNY 90,000,000.00 in Q1 2022[19] - Cash outflow for repayment of debts was CNY 20,200,000.00, compared to CNY 5,000,000.00 in Q1 2022[19] - The company reported a decrease in cash flow from operating activities related to other business activities, totaling CNY 9,119,903.24, down from CNY 19,805,193.77 in Q1 2022[18] Expenses - Total operating costs for Q1 2023 were ¥228,356,493.21, down 6.0% from ¥242,656,388.86 in Q1 2022[15] - Research and development expenses for Q1 2023 were ¥22,660,128.74, a decrease of 4.6% from ¥23,745,421.82 in Q1 2022[15] - The company’s financial expenses rose to ¥2,799,419.24 in Q1 2023, up from ¥716,697.27 in Q1 2022, indicating a significant increase in interest expenses[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,314[8] - The company reported non-recurring gains of ¥6,782,709.93 for the period, after accounting for tax effects and minority interests[7] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with Q1 2022[17] Cash and Cash Equivalents - The company's cash and cash equivalents increased to ¥975,341,333.35 in Q1 2023, slightly up from ¥969,399,325.09 in Q1 2022[12] - Cash and cash equivalents at the end of the period were CNY 181,670,560.69, slightly down from CNY 184,046,470.97 at the end of Q1 2022[19] - Revenue from sales of goods and services received cash of CNY 293,060,884.07, an increase of 9.9% from CNY 266,566,667.91 in Q1 2022[18] - The company reported an investment income of ¥4,739,753.75 in Q1 2023, significantly higher than ¥555,766.54 in Q1 2022[16]